First Trust Direct Indexing L.P. Has $1.84 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

First Trust Direct Indexing L.P. grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 10.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,239 shares of the medical research company’s stock after acquiring an additional 1,804 shares during the period. First Trust Direct Indexing L.P.’s holdings in Edwards Lifesciences were worth $1,838,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in EW. DSM Capital Partners LLC bought a new position in Edwards Lifesciences during the fourth quarter worth $28,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth $34,000. Riverview Trust Co acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $34,000. Pingora Partners LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $38,000. Finally, Burkett Financial Services LLC acquired a new position in Edwards Lifesciences in the fourth quarter worth about $46,000. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Mizuho lifted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Wells Fargo & Company upped their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research note on Friday, April 26th. Oppenheimer lifted their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Finally, Citigroup upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $98.00 to $105.00 in a research report on Wednesday, May 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.18.

Edwards Lifesciences Stock Down 0.2 %

NYSE:EW opened at $91.08 on Friday. The firm has a market capitalization of $54.88 billion, a price-to-earnings ratio of 39.26, a price-to-earnings-growth ratio of 3.33 and a beta of 1.11. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The stock’s 50 day moving average price is $88.10 and its two-hundred day moving average price is $85.64.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Equities research analysts expect that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total value of $2,487,999.50. Following the completion of the sale, the director now directly owns 4,486 shares in the company, valued at $380,278.22. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total transaction of $2,487,999.50. Following the completion of the transaction, the director now owns 4,486 shares of the company’s stock, valued at approximately $380,278.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total value of $437,700.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $4,108,777.44. The disclosure for this sale can be found here. Insiders sold 90,499 shares of company stock valued at $7,866,511 in the last quarter. Company insiders own 1.27% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.